Trial Profile
Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CASSINI
- Sponsors Janssen Research & Development
- 18 Jun 2019 Results published in the Annals of Internal Medicine
- 04 Jun 2019 Results analysing benefit of rivaroxaban thromboprophylaxis in pancreatic cancer patients during intervention period presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 12 Feb 2019 Results published in the New England Journal of Medicine